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1. Introduction 
Type 2 diabetes mellitus (T2DM) is currently considered as a global health problem where 
about six people die every minute from the disease worldwide. This rate will make T2DM 
one of the world’s most prevalent causes of preventable mortality [1]. T2DM is caused by 
impaired glucose tolerance (IGT) as a result of insulin resistance and consequential islet β-
cell exhaustion, with ensuing insulin deficiency [2]. In individuals with IGT, numerous 
genetic, host-related, and environmental factors contribute to the progression of insulin 
resistance to T2DM [3-7]. Obesity, however, is a major cause of insulin resistance [5] and can 
be complicated by metabolic dysregulation including hypertension and dyslipidemia 
[known collectively as the metabolic syndrome] which is a precursor of T2DM. The 
dyslipidemia involves high levels of triacylglycerides and circulating fatty acids originating 
from the diet or accelerated lipolysis in adipocytes. Direct exposure of muscle cells to these 
fatty acids impairs insulin-mediated glucose uptake and, therefore, may contribute to 
insulin resistance [8,9]. Within the last decade, a hypothesis was proposed to explain the 
pathogenesis of T2DM that connects the disease to a state of subclinical chronic 
inflammation [10,11]. Inflammation is a short-term adaptive response of the body elicited as 
a principle component of tissue repair to deal with injuries and microbial infections (e.g., 
cold, flu, etc.). It can be also elevated in chronic conditions such as peripheral neuropathy, 
chronic kidney disease and fatty liver. While the influence of fats is well known (see below), 
current thinking suggests that abnormal levels of chemokines released by the expanding 
adipose tissue in obesity activate monocytes and increase the secretion of pro-inflammatory 
adipokines. Such cytokines in turn enhance insulin resistance in adipose and other tissues, 
thereby increasing the risk for T2DM [12,13]. Together, lipid toxicity and low-grade 
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inflammation appear to be major assaults on insulin sensitivity in insulin-responding tissues 
[9,14,15]. 
Activation of innate immunity promotes various inflammatory reactions that provide the 
first line of defense the body invokes against microbial, chemical, and physical injury, 
leading to repair of damage, isolation of microbial infectious threats and restoration of tissue 
homeostasis [16,17]. Inherited variations in the degree of innate immune response may 
determine the lifetime risk of diseases upon exposure to adverse environmental stimuli [18]. 
Therefore, innate immune responses can be viewed as the outcome of interaction between 
genetic endowment and the environment [19].  
This article was undertaken in an attempt to evaluate the current knowledge linking vitamin 
intake to attenuating inflammation, and thereby reducing the risk of T2DM and its 
complications. 
2. Micronutrients, T2DM and inflammation 
Factors that attenuate inflammation could provide an important public health tool to reduce 
the burden of diseases related to this pathway, such as obesity, T2DM and cardiovascular 
diseases, in the general population. The feasibility of modulating innate immunity-related 
inflammation as an approach for the prevention of T2DM is based on reports that evaluated 
the efficacy of anti-inflammatory pharmaceutical agents on disease manifestation and 
outcome [12,20]. 
A therapeutic strategy for T2DM that would act primary on the inflammatory system has 
been proposed in the form of salicylates, an anti-inflammatory agent long known to have a 
hypoglycemic effect [21,22]. Nonsteroidal anti-inflammatory drugs (NSAIDs) and 
cyclooxygenase inhibitors are able to enhance glucose-induced insulin release, improve 
glucose tolerance, and increase the effect of insulin in patients with T2DM [15,23,24]. In 
humans, treatment with NSAIDs improved various biochemical indices associated with 
T2DM [25]. Although these observations support the notion that inflammation plays a 
pivotal role in T2DM, attenuating inflammation as a strategy for disease prevention in a 
public health setting will necessitate a substantially different perspective. In this case, a 
strategy that can be introduced into the general population with the least (if any) side effects 
and the maximal preventive outcome should be adopted. In this context, a nutritional 
intervention approach would be a desirable option. 
Numerous nutritional factors can modify innate immune-related responses and, 
subsequently, modify the risk of a range of chronic conditions. With respect to T2DM, the 
consensus of available information suggests that micronutrient intake modulates the innate 
immune system [26] and can subsequently influence the predisposition to [and prevention 
of] disease [26-28]. By virtue of this observation, the hope is that the outcome of nutritional 
supplementation can be simply monitored via its modifying action on the levels of 
inflammatory biomarkers. Many micronutrients exhibit well-characterized anti-
inflammatory or immunomodulatory functions [25]. Vitamins (e.g., D, E, and C), certain 
fatty acids (e.g., omega-3 fatty acid) and trace elements (e.g., selenium, zinc, copper and 
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iron) are known to improve the overall function of the immune system, prevent excessive 
expression and synthesis of inflammatory cytokines, and increase the ‘oxidative burst’ 
potential of macrophages [25]. Vitamin C is the major water-soluble dietary antioxidant anti-
inflammatory factor, exerting its actions in the aqueous phase. In contrast, vitamins E and D 
are lipid-soluble and protect against inflammation in the lipid phase, e.g., adipocytes. 
Although acting primarily in different phases, these micronutrients can function together by 
regenerating each other in the reduced form [29]. Indeed, exploring the possibility that 
supplementation with selected micronutrients can attenuate obesity-related inflammation in 
order to delay the development of T2DM should be considered alongside existing public 
health practices to reduce the disease rising rates. 
3. Vitamin C 
Vitamin C (ascorbic acid or ascorbate), an essential nutrient, is a 6-carbon lactone and the 
primary hydrophilic antioxidant found in human plasma [30]. Circulating concentrations of 
ascorbate in blood are considered adequate if at least 28 μM, but they are considerably 
higher in most cells due to active transport. The daily recommended dietary allowance for 
vitamin C is 75 mg for women and 90 mg for men, with an additional 35 mg for smokers 
due to the higher metabolic turnover of the vitamin in this group as compared to non-
smokers [31]. Ascorbate appears in the urine at intakes of roughly 60 mg/day. However, the 
results of a depletion/repletion study in healthy young women showed that ascorbate 
plasma and white blood cell concentrations only saturate at intakes of 200 mg/day or higher 
[32]. These results suggest that the current dietary recommendations may not provide 
tissue-saturating ascorbate concentrations [33]. Indeed, epidemiologic findings suggest that 
serum ascorbic acid deficiency may be relatively common. For example, a recent cross-
sectional survey of healthy young adults of the Toronto Nutrigenomics and Health (TNH) 
Study reported that 1 out 7 individuals is deficient in serum ascorbic acid [34]. 
Vitamin C has an important role in immune function and various oxidative and 
inflammatory processes, such as scavenging reactive oxygen species (ROS), preventing the 
initiation of chain reactions that lead to protein glycation [31;35] and protecting against lipid 
peroxidation [31, 36]. The oxidized products of vitamin C, ascorbyl radical and 
dehydroascorbic acid, are easily regenerated to ascorbic acid by glutathione, NADH or 
NADPH [31]. In addition, ascorbate can recycle vitamin E and glutathione back from their 
oxidized forms [31, 33]. For this reason, there has been interest in determining whether 
vitamin C might be used as a therapeutic agent against the oxidative stress and subsequent 
inflammation associated with T2DM.  
A variety of epidemiologic studies have assessed the effect of vitamin C on biomarkers of 
oxidation, inflammation and/or T2DM risk [30, 37-42]. A large cross-sectional evaluation of 
healthy elderly men from the British Regional Heart Study reported that plasma vitamin C, 
dietary vitamin C and fruit intake were inversely correlated with serum CRP and tissue 
plasminogen activator [tPA], a biomarker of endothelial disfunction [134]. However, only 
plasma vitamin C was inversely associated with fibrinogen levels [30]. Another cross-
sectional study of adolescents aged 13-17 found inverse associations between intakes of 
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fruit, vegetables, legumes and vitamin C and urinary F2-isoprostane, CRP, and IL-6 [43]. A 
recent cross-sectional evaluation of healthy young adults from the TNH Study 
demonstrated that serum ascorbic acid deficiency is associated with elevated CRP and other 
factors related to the metabolic syndrome such as waist circumference, BMI and high blood 
pressure [34]. Finally, the European Prospective Investigation of Cancer (EPIC)-Norfolk 
Prospective Study examined the link between fruit and vegetable intake and plasma levels 
of vitamin C and risk of T2DM. During 12-year follow-up, 735 incident cases of diabetes 
were identified among nearly 21,000 participants [44]. A significant inverse association was 
found between plasma levels of vitamin C and risk of diabetes (OR=0.38, 95% CI=0.28-0.52). 
In the same study, a similar association was observed between fruit and vegetable intake 
and T2DM risk (OR=0.78, 95% CI=0.60-1.00) [44].  
Despite epidemiologic findings generally pointing towards an association between increased 
vitamin C and reduced oxidation and inflammation, intervention trials assessing the effect of 
vitamin C supplementation on various markers of T2DM have yielded inconsistent results. 
One randomized, cross-over, double-blind intervention trial reported no improvement in 
fasting plasma glucose and no significant differences in levels of CRP, IL-6, IL-1 receptor 
agonist or oxidized LDL after supplementation with 3000 mg/day of vitamin C for 2 weeks in a 
group of 20 T2DM patients, compared to baseline levels [45]. Chen and colleagues performed a 
randomized, controlled, double-blind intervention on a group of 32 diabetic subjects with 
inadequate levels of vitamin C and found no significant changes in either fasting glucose or 
fasting insulin after intake of 800 mg/day of vitamin C for 4 weeks [46].  
On the other hand, Wang and colleagues showed that the red blood cell sorbitol/plasma 
glucose ratio was reduced after supplementation with 1000 mg/day vitamin C for 2 weeks in 
a group of eight diabetics, although no differences were found in fasting plasma glucose 
[47]. Since sorbitol is a product of the pro-oxidative polyol pathway, this observation may 
suggest an inhibition of the polyol pathway by vitamin C among subjects with diabetes. 
Another study has shown that daily intake of ascorbic acid at 2000 mg/day improved fasting 
plasma glucose, HbA1c, cholesterol levels and triglycerides in 56 diabetics [48]. In 
agreement, Paolisso et. al. found that 1000 mg/day of vitamin C for 4 months improved LDL 
and total cholesterol, fasting plasma insulin and free radicals, although it did not affect 
triglycerides or HDL levels in a group of 40 diabetics [49]. 
Overall, it remains unclear whether vitamin C intake has an effect on factors related to 
T2DM. Although the epidemiologic evidence suggests that vitamin C, whether as a 
supplement or as part of a diet rich in fruits and vegetables, beneficially affects 
inflammatory markers and disease risk, the results of intervention trials in T2DM are 
conflicting. Small sample sizes, genetic variation, short intervention duration, insufficient 
dosage and disease status of the assessed cohorts may account for the lack of effect and the 
inconsistent outcomes observed in intervention studies. However, it is possible also that the 
status of vitamin C deficiency is a result of the oxidative and pro-inflammatory challenges 
associated with T2DM rather than a determinant of disease pathogenesis. Therefore, further 
research and long-term prospective studies are needed to elucidate the role of vitamin C as a 
modulator of inflammation and T2DM risk, and to evaluate its potential role as a preventive 
agent at a population level.  
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4. Vitamin E 
Vitamin E encompasses a group of 8 compounds, including α, β, γ, and δ tocopherols and α, 
β, γ, and δ tocotrienols, with differing biological activities. Each compound contains a 
hydroxyl-containing chromanol ring with a varying number and position of methyl groups 
between the α, β, γ, and δ forms [29]. It is known to have a significant impact on improving 
a variety of immune functions [50]. Supplementation with vitamin E increases the rate of 
lymphocyte proliferation by enhancing the ability of T cells to undergo cell division cycles 
[51]. The effective anti-inflammatory action of vitamin E was substantiated from 
observations such as the increased expression of the IL-2 gene and IL-1 receptor antagonist 
and the decreased expression of IL-4 following vitamin E supplementation in animal models 
[50]. Furthermore, vitamin E reduced the serum levels of inflammatory factors such as IL-1β, 
IL-6, TNF-α , PAI-1, and CRP in T2DM patients [52, 53]. Furthermore, vitamin E 
downregulates NFκB [52], the principal mediator of inflammatory signaling cascade and its 
potent lipophilic antioxidant effect on internal and external cell membranes as well as 
plasma lipoproteins, notably LDL. Based on this latter characteristic, studies in both animal 
models and humans have demonstrated that vitamin E intake blocks LDL lipid 
peroxidation, prevents the oxidative stress linked to T2DM-associated abnormal metabolic 
patterns [hyperglycemia, dyslipidemia, and elevated levels of FFAs], and, subsequently, 
attenuates cytokine gene expression [50, 52, 56, 57]. Despite these findings, a recent study 
evaluated the effects of a combination of vitamin C (1000 mg/day) and vitamin E (400 
IU/day) for four weeks on insulin sensitivity in untrained and trained healthy young men 
and concluded that such supplementation may preclude the exercise-induced amelioration 
of insulin resistance in humans [58]. This may relate to the source of vitamin E used, i.e., α-, 
β-, γ-, or δ-tocopherol [59].  
Overall, the immunomodulatory, anti-inflammatory and anti-oxidative functions of vitamin 
E strongly support its possible application in designing effective prevention and/or 
treatment protocols for T2DM [25, 56]. Current practices for diabetes prevention in the 
general population include lifestyle change, dietary intervention and exercise. Vitamin E 
supplementation may further aid in T2DM prevention and control through its anti-oxidant, 
anti-inflammatory and immunomodulatory properties. It seems reasonable, therefore, to 
suggest supplementation with vitamin E together with lifestyle change may be combined 
into a single program to enhance the success and effectiveness of intervention. This strategy 
could be more efficient in reducing the low-grade inflammation associated with pre-clinical 
T2DM and, subsequently the disease burden, than when a single approach is considered. 
Moreover, such a combined strategy can be introduced in general practice settings and in a 
population-based fashion with low expenditure and minimal side effects. 
5. Vitamin D 
The role of vitamin D in calcium and phosphorus homeostasis and bone metabolism is well 
understood. However, more recently vitamin D and calcium homeostasis have also been 
linked to a number of conditions, such as neuromuscular function, cancer, and a wide range 
of chronic diseases, including autoimmune diseases, atherosclerosis, obesity, cardiovascular 
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diseases, diabetes and associated conditions such as the metabolic syndrome and insulin 
resistance [25, 60-63]. In T2DM, the role of vitamin D was suggested from the presence of 
vitamin D receptors (VDR) in the pancreatic β-islet cells [63]. In these cells, the biologically 
active metabolite of vitamin D (i.e., 1,25-dihydroxy-vitamin D; 1,25[OH]D) [64] enhances 
insulin production and secretion via its action on the VDR [63]. Indeed, the presence of 
vitamin D binding protein (DBP), a major predictor of serum levels of 25(OH)D and 
response to vitamin D supplementation [65, 66], and VDR initiated several studies 
demonstrating a relationship between single nucleotide polymorphisms (SNPs) in the genes 
regulating VDR and DBP and glucose intolerance and insulin secretion [67-69]. This further 
supports a role for vitamin D in T2DM and may explain the reduced overall risk of the disease 
in subjects who ingest >800 IU/d of vitamin D [61,70]. However, an alternative, and perhaps 
related, explanation was recently proposed for the role of vitamin D in T2DM prevention 
based on its potent immunomodulatory functions [71-73]. 1,25(OH)D modulates the 
production of the immunostimulatory IL-12 and the immunosuppressive IL-10 [74] and VDRs 
are present in most types of immune cells [75]. In this respect, supplementation with vitamin D 
[76] or its bioactive form, 1,25(OH)D [64], improved insulin sensitivity by preventing the 
excessive synthesis of inflammatory cytokines. This effect of vitamin D on cytokine synthesis is 
due to its interaction with vitamin D response elements (VDRE) present in the promoter 
region of cytokine-encoding genes. This interaction downregulates the transcriptional 
activities of cytokine genes and attenuates the synthesis of the corresponding proteins [76]. 
Vitamin D also deactivates NFκB, which transcriptionally upregulates the pro-inflammatory 
cytokine-encoding genes [77]. Downregulating the expression of NFκB and downstream 
cytokine genes inhibits β-cell apoptosis and promotes their survival [76].  
As reviewed by Pittas et al [78], a number of cross-sectional studies in both healthy and 
diabetic cohorts have shown an inverse association between serum 25(OH)D and glycemic 
status measures such as fasting plasma glucose, oral glucose tolerance tests, hemoglobin A1c 
(HbA1c), and insulin resistance as measured by the homeostatic model assessment (HOMA-
R), as well as the metabolic syndrome [79-84]. For example, data from the National Health 
and Nutrition Examination Survey (NHANES) showed an inverse, dose-dependent 
association between serum 25(OH)D and diabetes prevalence in non-Hispanic whites and 
Mexican Americans, but not in non-Hispanic blacks [81,84]. The same inverse trend was 
observed between serum 25(OH)D and insulin resistance as measured by HOMA-R, but 
there was no correlation between serum levels of vitamin D and β-cell function, as measured 
by HOMA-β [81,84]. Data from the same cohort also showed an inverse association between 
25(OH)D and prevalence of the metabolic syndrome [81].  
In prospective studies, dietary vitamin D intake has been associated with incidence of 
T2DM. For example, data from the Women’s Health Study showed that, among middle-
aged and older women, taking >511 IU/day of vitamin D reduced the risk of developing 
T2DM, as compared to ingesting 159 IU/day [85]. Furthermore, data from the Nurses Health 
Study also found a significant inverse correlation between total vitamin D intake and T2DM 
risk, even after adjusting for BMI, age, and non-dietary covariates [70]. Intervention studies 
have shown conflicting results about the effect of vitamin D on T2DM incidence. One study 
reported that supplementation with 1,25[OH]2D3 for 1 week did not affect fasting glucose or 
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insulin sensitivity in 18 young healthy men [86]. Another study found that, among 14 T2DM 
patients, supplementing with 80 IU/day of 1 α-OHD3 ameliorated insulin secretion but did 
not improve glucose tolerance after a 75 g oral load [87]. Yet another study showed that, 
among 65 middle-aged men who had IGT or mild T2DM and adequate serum vitamin D 
levels at baseline, supplementation with 30 IU/day of 1-α-OHD3 for 3 months affected neither 
fasting nor stimulated glucose tolerance [88]. However, in a cross-over design, 20 diabetics 
with inadequate vitamin D serum levels who were given 40 IU/day of 1,25-OHD for 4 days 
had improved insulin secretion, but showed no changes in fasting or stimulated glucose or 
insulin concentrations [89]. Although the short duration of this cross-over trial may account for 
the lack of a significant overall effect, the results suggest that improving vitamin D status can 
modulate factors associated with the development and progression of T2DM.  
The data from a 2-year-long trial designed to assess the effects of vitamin D3 or 1-α-OHD3 
supplementation on bone health in non-diabetic postmenopausal women were analyzed a 
posteriori and found no significant effect on fasting glucose levels [90]. A post-hoc analysis of 
data from a 3-year trial for bone health showed that daily supplementation with 700 IU of 
vitamin D3 and 500 mg of calcium citrate malate did not change blood glucose levels or 
insulin resistance in elderly adults with normal glucose tolerance. These measures, however, 
were significantly improved in subjects with IGT at baseline [91]. In this trial the effect of 
fasting glucose levels in the high-risk group (i.e., IGT) was similar to that observed in the 
Diabetes Prevention Program after an intensive lifestyle intervention or metformin 
treatment [92]. Taken together, the available information warrants exploring the possibility 
that vitamin D (alone or in combination with calcium) can be employed in developing 
population-based strategies for T2DM prevention and control.  
6. β-carotene and lycopene 
As previously stated, oxidative stress is involved in the development and complications of 
T2DM [60]. Patients with T2DM exhibit a reduced antioxidative defence, which negatively 
correlates with glucose levels and duration of the disease [93]. In diabetic subjects, the lack 
of metabolic homeostasis, the increased plasma ROS generation and the decreased efficiency 
of inhibitory and scavenger systems [60], all can that result in a status of oxidative stress that 
can have an etiological role in T2DM complications, e.g., retinopathy, chronic kidney 
disease, and cardiovascular diseases [94]. The synthesis of ROS was proposed to be 
primarily due to hyperglycaemia [95] resulting in stimulation of the polyol pathway, 
formation of advanced glycosylation endproducts, and subsequent formation of ROS. 
Hyperinsulinaemia, insulin resistance and inflammation, may all play a role in the synthesis 
of  ROS in pre-diabetic and diabetic patients [60]. 
As we reviewed recently, the risk of T2DM can be mitigated by increased antioxidants 
intake [60]. Intake of α- and β-carotene and lycopene has been shown to improve glucose 
metabolism in subjects at high risk of T2DM [96], and glucose metabolism has been 
associated with oxidative stress [95]. Indeed, diabetic patients have shown a predominantly 
elevated levels of lipid peroxidation (F2-isoprostanes) [97]. In vivo lipid peroxidation, 
measured as F2-isoprostanes, apprears to be influenced by the consumption of dietary 
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components such as antioxidants. It is therefore critical to examine the dietary effects of α- 
and β-carotene and lycopeneon lipid peroxidation in patients with T2DM. The relationship 
between plasma levels of antioxidants and markers of oxidative stress and inflammation 
have been described in healthy population [58,98] and is yet to be identified in diabetic 
subjects. This will allow us to better define the role of α- and β-carotene and lycopene in 
attenuating inflammation and modulating the oxidative stress during the course of T2DM 
development and progression.  
7. T2DM complications: Cardiometabolic disease 
It is well-established that T2DM is a risk factor for cardiometabolic diseases. Studies from 
our group demonstrated a relationship between T2DM and its risk factors and 
cardiometabolic disease markers [98,99]. We observed an apparent profile of metabolic 
phenotypes and inflammatory biomarkers, known to be related to the cardiometabolic 
disease risk, that emerges with the susceptibility to T2DM. These findings allowed us to 
establish a composite metabolic trait that lead to the development of improved strategies for 
early risk prediction and intervention.  
In the same study population, we further demonstrated an association between plasma 
vitamin D level and T2DM risk, e.g., insulin resistance [100]. We found that the likelihood that 
T2DM develops and results in related complications is further increased as plasma vitamin D 
levels decrease. These studies highlights the possibility that micronutrient supplementation 
can be employed in the prevention of various T2Dm complications including cardimetabolic 
diseases. Moreover, there is a need to develop adequately powered randomized controlled 
clinical trials to evaluate the value of replenishment of vitamin D on T2DM and the related 
conditions, e.g., obesity, insulin resistance and cardiovascular diseases, as an approach for an 
effective population based strategy for disease prevention. 
8. Public health prespectives 
Introducing novel and effective prevention strategies in a public health setting necessitates 
considering approaches with the least [if any] side effects and the maximal preventive 
efficacy and outcome. Furthermore, the heterogeneity of the general Western population in 
terms of culture, location and resources renders creating a unified intervention program a 
formidable endeavour. In this context, applying nutritional intervention as an approach to 
attenuate inflammation and oxidative stress would be a feasible public health strategy for 
the T2DM. A conceptual model need to be implemented to improve the availability and 
accessibility of nutritious food as a factor that can be integrated into a comprehensive public 
health intervention strategy aimed at T2DM prevention. 
Combining micronutrients supplementation or encouraging the consumption of nutritious 
diet should be explored in pre-diabetic subjects and the outcome should be compared to the 
effect(s) of changing current practices, such as lifestyle change, dietary intervention and 
exercise. The effectiveness of lifestyle-change intervention programmes for pre-diabetes also 
shows a promising effect on the reduction of overall incidence of T2DM or its complications, 
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and it can be implemented in general clinical practice [95]. A lifestyle-change programme 
including increased exercise and diet change (either by reduction in glycemic load or 
reduced-fat diet) demonstrated a significant difference between control and intervention 
groups in markers for risk of progression to T2DM including weight, BMI, and waist 
circumference [101]. In general, current approaches for the prevention of T2DM have been 
shown to be effective in delaying or preventing the progression from pre-diabetes to 
diabetes [102]. In patients with insulin resistance, these practices are known to improve 
insulin sensitivity and the overall predisposition to T2DM [103]. On the other hand, 
increasing intake of vitamin D to greater than 800 IU daily along with 1200 mg of calcium 
was reported to reduce the risk of developing T2DM by 33% [78]. In agreement, healthy 
older adults with impaired fasting glucose showed significant improvement in attenuating 
the glycemic response and insulin resistance when they increased the vitamin D to 700 IU/d 
and calcium to 500 mg/d for 3 yrs [70]. It seems reasonable, therefore, to suggest that the two 
preventive approaches for T2DM, i.e., micronutrient supplementation and lifestyle change, 
may be combined into a single successful intervention programme. This strategy may be 
more efficient in reducing the burden of the disease in the general population and in 
vulnerable subpopulations than when a single approach is proposed. Moreover, such a 
combined approach may be introduced into the general practice setting and to the general 
population with low expenditure and minimal side effects [25,60]. 
Overall, the current state of knowledge warrants further study into the extent to which 
micronutrients can modify the association between markers of inflammation  and oxidative 
stress and early stages of T2DM. There is evidence supporting the idea that vitamin 
supplementation can modify the genotype-phenotype association within the innate immune 
response (i.e., the pro-inflammatory and inflammatory markers), and that it has an 
ameliorating effect on oxidative stress and the subsequent inflammatory signalling. This 
proposition may provide the mechanism by which nutritional factors prevent or delay 
disease development and can be introduced into the general population, as well as 
susceptible subpopulations. In relation to the current preventive approaches for T2DM, e.g., 
lifestyle changes, exercise, and dietary intervention, exploring the efficacy of micronutrient 
supplementation on attenuating oxidative stress, the innate immune response and the 
ensuing inflammation and evaluating the outcome of this strategy on T2DM incidence may 
be assessed through a series of prospective population-based studies, first, to determine the 
feasibility and effectiveness of this protocol; second, to validate and evaluate this strategy 
and ensure replication of results; and, third, to monitor the outcome to quantify the overall 
preventive response in comparison with the current approaches.  
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